INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES国际感染病杂志
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES(英文缩写 INT J INFECT DIS),ISSN 1201-9712,eISSN 1878-3511,中文译名:国际感染病杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 12.073 | Q1 |
| 2022 | 8.400 | Q1 |
| 2023 | 4.800 | Q1 |
| 2024 | 4.300 | Q1 |
| 2025 | 4.600 | Q1 |
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES 最新收录文献
-
1. Host factors, not Mycobacterium tuberculosis lineage, predict unfavorable outcomes in drug-susceptible pulmonary tuberculosis: evidence from RePORT-Brazil.
1. 宿主因素而非结核分枝杆菌谱系可预测药物敏感性肺结核的不良结局：来自RePORT-巴西的证据PMID:期刊:日期:2026-10-04To determine whether Mycobacterium tuberculosis (Mtb) lineage was independently associated with clinical presentation and unfavorable treatment outcomes in drug-susceptible pulmonary tuberculosis (TB) in a large Brazilian cohort. We analyzed 900 rifampicin- and isoniazid-susceptible Mtb isolates from adults enrolled in the multicenter RePORT-Brazil cohort using 24-loci MIRU-VNTR genotyping. Treatment outcome analyses included 772 participants with complete follow-up. Associations between lineage and a composite unfavorable outcome (death, failure, or recurrence) were evaluated using pre-specified multivariable Firth logistic regression adjusted for demographic, clinical, and geographic factors. Thirteen lineages were identified, predominantly LAM (56.7%) and Haarlem (30.6%). Although lineage distribution varied by region, lineage was not independently associated with unfavorable outcomes. HIV infection and older age were the strongest predictors. Baseline clinical features and treatment outcomes were largely similar across lineages. Among 43 participants with positive month-2 cultures, 22 were genotyped and in 5/22 (22.7%) the month-2 isolate belonged to a different lineage from the baseline isolate, consistent with reinfection or mixed infection. In drug-susceptible pulmonary TB, host-related factors, rather than Mtb lineage, were more strongly associated with unfavorable treatment outcomes.
-
2. Intraventricular Vancomycin for Ommaya Reservoir-Associated Staphylococcus hominis Ventriculitis in a Very Preterm Infant with Disseminated Candidiasis: A Case Report.
2. 脑室内万古霉素治疗极早产儿播散性念珠菌病伴Ommaya储液囊相关人型葡萄球菌脑室炎：一例病例报告PMID:期刊:日期:2026-10-04Coagulase-negative staphylococci (CoNS) commonly infect Ommaya reservoirs, but data on intraventricular (IVT) vancomycin in neonates are very limited. We report a very preterm infant with oxacillin-resistant Staphylococcus hominis (ORSH) ventriculitis who was successfully treated with IVT vancomycin after systemic antibiotic failure. A female infant born at 29+2 weeks (birth weight 1,250 g) developed disseminated Candida albicans infection involving blood, central nervous system, eyes, and urinary tract. Progressive hydrocephalus required Ommaya reservoir placement at postmenstrual age of 37+2 weeks. Three weeks later, she developed ORSH ventriculitis. Intravenous vancomycin for 3 weeks followed by linezolid for 3 weeks failed to eradicate the infection. IVT vancomycin (5 mg every 48 h, 7 doses) was administered via the Ommaya reservoir together with systemic linezolid. The CSF vancomycin trough before the second dose was 18.56 μg/mL; subsequent troughs were 23.7 μg/mL and 18 μg/mL, suggesting a dose-related change in CSF vancomycin exposure. CSF cultures turned to negative after 5 IVT doses and remained negative on three consecutive samples. No ototoxicity or neurologic worsening was observed. IVT vancomycin at 5 mg every 48 h via an Ommaya reservoir may represent a safe and effective salvage treatment for CoNS ventriculitis in preterm infants when systemic antibiotics fail. Therapeutic drug monitoring (TDM) may be particularly important because CSF vancomycin levels vary greatly between individuals. This case provides one of the first serial CSF vancomycin trough measurements in a very preterm infant, suggesting a potential empiric starting approach for IVT vancomycin in this population.
-
3. Prediction of response to Buruli ulcer treatment shortening with novel beta-lactam-containing antimicrobial combinations.
3. 预测含有新型β-内酰胺类抗菌药物联合方案缩短布鲁里溃疡治疗疗程的应答情况PMID:期刊:日期:2026-10-02Whilst rifampicin (RIF, q.d.) plus clarithromycin (CLA, b.i.d.) for 8 weeks is an effective treatment for Buruli ulcer (BU), this prolonged regimen presents challenges for adherence, particularly in community-based settings. Using a mechanism-based modelling and simulation framework, informed by In vitro bactericidal activity data, this study aimed to predict whether adding amoxicillin-clavulanate (AMX/CLV) could shorten BU treatment. In vitro time-kill data for RIF, CLA, and AMX/CLV, alone and in combination, against Mycobacterium ulcerans isolates were analysed using a nonlinear mixed-effects approach. Clinical trial simulations (n=70/arm) then assessed bacterial eradication times for standard therapy versus AMX/CLV-containing regimens, including higher RIF doses, while accounting for population pharmacokinetic variability and drug skin penetration. In vitro time-kill analyses showed that, excluding isolate ITM070290, AMX/CLV-containing combinations provide comparable or superior potency and faster killing rates than the standard of care. Clinical trial simulations predicted these regimens can reliably achieve bacterial eradication within 4 and 6 weeks for moderate and high bacterial loads, respectively, with only one exception requiring over 8 weeks in high-burden scenarios. Incorporating AMX/CLV alongside optimized RIF doses shows strong potential to shorten BU treatment from 8 weeks down to 4-6 weeks, supporting its ongoing evaluation in clinical trials.
-
4. Whole-Genome Sequencing of Mycobacterium tuberculosis in Lebanon: Updated Genomic Insights.
4. 黎巴嫩结核分枝杆菌全基因组测序：更新的基因组学见解PMID:期刊:日期:2026-10-01Lebanon is a low-burden tuberculosis (TB) country with a complex demographic context shaped by migration, socioeconomic instability, and recent healthcare disruptions. We aimed to characterize the population structure, drug resistance, and transmission dynamics of Mycobacterium tuberculosis using whole-genome sequencing (WGS). WGS was performed on 218 M. tuberculosis isolates collected in Lebanon between 2018 and 2024, of which 196 passed quality control. TB-Profiler identified lineages and resistance-associated mutations, with results compared against available phenotypic drug susceptibility testing (DST) and line-probe assays (LPA). TB-Annotator provided high-resolution sub-lineage classification, phylogenomic contextualization within a global MTB dataset, and identification of genomic clusters. Lineage 4 predominated (71.4%), followed by Lineage 3 (15.3%), Lineage 2 (6.6%), and Lineage 1 (6.1%), with a single rare Lineage 7 isolate. Resistance-associated mutations were identified in 41.3% of isolates, including MDR-TB (7.1%) and pre-XDR-TB (2.6%). WGS-based resistance prediction showed high concordance (91.8%-100%) with phenotypic DST and LPA. Fourteen genomic clusters included 29/195 isolates (14.9%); incorporation of publicly available Lebanese genomes identified additional Lineage 4-associated clusters, supporting ongoing local transmission. This nationwide WGS study revealed a highly diverse MTB population in Lebanon and supports the integration of WGS into routine TB surveillance and control activities.
-
5. Impact of prolonged co-trimoxazole prophylaxis on colonisation with antibiotic resistant bacteria in persons newly diagnosed with HIV-infection: CoTrimResist - a randomised placebo-controlled trial.
5. 长期复方磺胺甲噁唑预防用药对新诊断HIV感染者抗生素耐药细菌定植的影响：CoTrimResist——一项随机安慰剂对照试验PMID:期刊:日期:2026-09-29To assess whether prolonged co-trimoxazole prophylaxis for people with HIV in sub-Saharan Africa increases colonisation with antibiotic-resistant bacteria. The CoTrimResist trial (NCT03087890) randomised newly diagnosed Tanzanian adults with HIV and CD4 counts >350/µL to daily co-trimoxazole or placebo for one year. Clinical data, rectal and nasopharyngeal/nasal swabs were collected at enrolment, two weeks, six months, and one year. Primary outcomes were carriage of extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) and Klebsiella species (ESBL-K), methicillin-resistant Staphylococcus aureus (MRSA), and penicillin-non-susceptible pneumococci (PNSP). Among 537 participants (median age 37 years; 77% female), 259 received co-trimoxazole and 278 placebo. Co-trimoxazole temporarily reduced nasal S. aureus carriage at two weeks (risk difference -7.3%; 95% CI -12.0% to -2.6%) and six months (-7.6%; 95% CI -13.9% to -1.3%), and MRSA at two weeks (-4.5%; 95% CI -8.0% to -1.1%). ESBL-EC colonisation increased more rapidly with co-trimoxazole. At one year, there were no between-group differences in colonisation rates, mortality or serious adverse events. Intercurrent use of other antibiotics was associated with increased carriage of ESBL-EC. Prolonged co-trimoxazole prophylaxis leads to transient reductions in S. aureus and MRSA and early increase in ESBL-EC, but shows no persistent effect on colonisation with antimicrobial-resistant bacteria at one year.
-
6. Imported mosquito-borne infectious diseases in travellers and migrants: Global patterns, clinical overlap, and prevention gaps-an umbrella review of 21 systematic reviews.
6. 旅行者和移民中输入的蚊媒传染病：全球模式、临床重叠与预防缺口——对21项系统评价的总括性综述PMID:期刊:日期:2026-09-29Imported mosquito-borne infectious diseases (MBIDs) pose public health challenges in nonendemic regions, but cross-disease evidence remains fragmented. We conducted an umbrella review of systematic reviews to identify gaps and inform clinical practice and research priorities. Five databases (PubMed, Embase, Scopus, Web of Science, and the Cochrane Library) were searched from inception to December 3, 2025, for systematic reviews on nine imported MBIDs, including chikungunya, dengue, Rift Valley fever, yellow fever, Zika, lymphatic filariasis, malaria, Japanese encephalitis, and West Nile fever. Only English-language publications were included. Epidemiological, clinical, and prevention data were extracted; methodological quality was assessed using AMSTAR 2; and evidence gaps were examined through bibliometric mapping. Of the 2,610 references, 21 systematic reviews were included, resulting in the synthesis of 1,946 studies from 1943 to 2025 across seven of the nine prespecified imported MBIDs. No eligible systematic reviews were identified for Japanese encephalitis or West Nile fever. Dengue had the most importation evidence mainly from Asia, with 42,264 European cases. Malaria had migration flows from West Africa and India. Yellow fever, Rift Valley fever, and lymphatic filariasis were rarely reported, although one migrant-focused review reported 2,449 filariasis cases in Europe. Clinical presentations, particularly fever, myalgia, and rash, overlapped. Severe malaria fatality was 5.1% (95% confidence interval [CI] 4.0-6.2%), dengue fatality was 0.08-12.5%, and yellow fever fatality was 28.6%. Only five reviews addressed prevention. The evidence was uneven: 66.4% of the studies were conducted in Europe and 0.6% in Africa; dengue and malaria dominated the output; and Rift Valley fever accounted for <1% of all studies. Methodological quality was critically low in 66.7% of the reviews and high in 9.5%. The evidence base for imported MBIDs reveals major asymmetries across diseases, outcomes, geographies, and populations, limiting evidence-based management of viral MBIDs, sustaining reliance on symptom-based approaches, and overlooking vulnerable populations.
-
7. Clinical and radiological outcomes of spinal tuberculosis: A retrospective study.
7. 脊柱结核的临床与影像学结局：一项回顾性研究PMID:期刊:日期:2026-09-29To characterise clinical and radiological features of spinal tuberculosis (TB) at presentation, mid-treatment and treatment completion. We conducted a retrospective study of patients diagnosed with spinal TB between 2011-2022 across three London hospitals. Demographic and clinical data were collected at presentation, mid-treatment and on treatment completion. MRI findings at each time point were classified using a standardised scoring system. Clinical symptoms were scored according to severity. Sixty-two cases were evaluated. Most were male (45/62, 73%) and migrants (52/62, 84%); median age was 33 years (IQR, 26-40). Back or neck pain was the predominant presenting symptom (55/62, 89%). The thoracic spine was most frequently involved (41/62, 66%), and over one-third had multi-level disease. Five patients (8%) had spinal cord compression; three required surgery. Median TB treatment length was 12 months (IQR, 12-12). Radiological and clinical scores both improved significantly during treatment, with greater improvement at 12 months than at 6 months. Radiological improvement correlated with clinical improvement at both time points. No TB-related deaths occurred; however, 12/62 (19%) experienced long-term complications. Patients with spinal TB may benefit from an individualised treatment duration guided by clinical and radiological response; further studies are required to clarify the optimal approach.
-
8. Temporal Trends and Serogroup Distribution of Invasive Meningococcal Disease in Istanbul, Türkiye, 2021-2025.
8. 2021-2025年土耳其伊斯坦布尔侵袭性脑膜炎球菌病的时间趋势和血清群分布PMID:期刊:日期:2026-09-29This population-based cohort study evaluates temporal trends, clinical characteristics, and serogroup distribution of Invasive Meningococcal Disease (IMD) in Istanbul, Türkiye, from 2021 to 2025. Poisson regression models were used to evaluate changes in incidence rates across age groups over the years, calculating Incidence Rate Ratios (IRRs) and 95% confidence intervals. A total of 77 confirmed IMD cases were identified. The median age was 7 years (1-17), and 54.5% of patients were male. Serogroup B was the predominant strain, and meningitis was the most frequent clinical presentation. The IMD incidence increased significantly from 0.04 per 100000 population in 2021 to 0.17 per 100000 population in 2025, with an IRR of 1.45 (95% CI: 1.22-1.73; p<0.001). Children aged 0-4 years experienced the highest IMD burden, with incidence increasing significantly from 0.29 per 100000 in 2021 to 1.06 per 100000 in 2025 (IRR=1.35, 95% CI: 1.05-1.74; p=0.019). Intensive care admission was required in 42.9% of patients, while the overall case-fatality rate was 6.5%, increasing to 9.1% among children aged 0-4 years. Serogroup B predominance and severe 0-4 age vulnerability highlight the importance of sustained surveillance.
-
9. Resurgence of measles in Japan, a highly vaccinated country: a risk assessment study.
9. 日本麻疹疫情再现：一项高风险疫苗接种国家的风险评估研究PMID:期刊:日期:2026-09-26Measles is a highly transmissible infectious disease that has re-emerged globally following disruption to vaccination programmes during the COVID-19 pandemic. This study quantitatively assessed the risk of measles outbreaks in Japan in 2026. The effective reproduction number (R) of measles was estimated using two different approaches. First, the cluster size distribution data were analysed using a branching process model, and possible associations between cluster size and characteristics of the primary case were explored. Second, the immune proportion of the Japanese population was estimated using vaccination coverage and seroepidemiological data. Using cluster size data from 2025-2026, R was 0.2 (95% confidence interval [CI] 0·1-0·3), with substantial overdispersion (dispersion parameter k 0·04, 95% CI 0·02-0·06). Larger clusters resulted from primary cases in unvaccinated people and children. In all age groups, more than 90% were considered immune, but adults aged 35-44 years were slightly more susceptible. Using the second method, R was estimated at 1.2 (95% CI: 0·3-5·5) and potential cumulative incidence at 1,702,000 (0-6,994,000). In early 2026, measles in Japan remains limited to minor outbreaks. If importation continues and people mix effectively, population immunity may be insufficient to prevent a major epidemic.
-
10. Asymptomatic tuberculosis among household contacts of active pulmonary tuberculosis cases: a systematic review and meta-analysis.
PMID:期刊:日期:2026-09-24To estimate the prevalence of asymptomatic tuberculosis (TB) among household contacts (HHC) of active pulmonary TB cases. This study followed the PRISMA guidelines and was registered in PROSPERO (CRD420261302883). We searched electronic databases and grey literature sources for studies published up to April 18, 2026. Studies were screened, and quality was assessed using the Joanna Briggs Institute tools. Data were analyzed using STATA version 17, and pooled values were estimated along with 95%CIs. Heterogeneity was assessed using I², and publication bias using funnel plots, Egger's test, and trim-and-fill analysis where appropriate. Of the 14,885 articles searched, 18 studies conducted in 12 countries involving 46,480 participants (HHCs) were included. The pooled prevalence of TB among asymptomatic HHCs was 4.0% (95%CI: 2.1-5.8%). Asymptomatic TB accounted for 51.0% (95%CI: 39.7-62.2%) of all identified TB cases. An estimated 2% (95%CI: 0.7-3.2%; I²: 90.67%) of TB-free asymptomatic contacts at baseline developed TB during follow-up. Male sex, chest X-ray suggestive of TB, cigarette smoking, and being a drug user were associated with asymptomatic TB. About half of TB cases among HHCs were asymptomatic, highlighting the need for integrated TB screening beyond symptoms to improve early detection and reduce transmission.